Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Asset Writedowns and Impairment: 2019-2025

Historic Asset Writedowns and Impairment for Akebia Therapeutics (AKBA) over the last 7 years, with Sep 2025 value amounting to $530,000.

  • Akebia Therapeutics' Asset Writedowns and Impairment fell 60.51% to $530,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 million, marking a year-over-year decrease of 8.45%. This contributed to the annual value of $4.2 million for FY2024, which is 163.00% up from last year.
  • Latest data reveals that Akebia Therapeutics reported Asset Writedowns and Impairment of $530,000 as of Q3 2025, which was up 1,204.17% from -$48,000 recorded in Q2 2025.
  • Over the past 5 years, Akebia Therapeutics' Asset Writedowns and Impairment peaked at $7.9 million during Q4 2021, and registered a low of -$9.6 million during Q4 2022.
  • In the last 3 years, Akebia Therapeutics' Asset Writedowns and Impairment had a median value of $471,000 in 2024 and averaged $587,364.
  • In the last 5 years, Akebia Therapeutics' Asset Writedowns and Impairment spiked by 3,569.06% in 2021 and then slumped by 221.12% in 2022.
  • Akebia Therapeutics' Asset Writedowns and Impairment (Quarterly) stood at $7.9 million in 2021, then tumbled by 221.12% to -$9.6 million in 2022, then skyrocketed by 102.84% to $273,000 in 2023, then spiked by 561.17% to $1.8 million in 2024, then slumped by 60.51% to $530,000 in 2025.
  • Its Asset Writedowns and Impairment was $530,000 in Q3 2025, compared to -$48,000 in Q2 2025 and $163,000 in Q1 2025.